Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
Fibrosis
Non-alcoholic fatty liver disease
Obese
Overweight
Journal
Obesity facts
ISSN: 1662-4033
Titre abrégé: Obes Facts
Pays: Switzerland
ID NLM: 101469429
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
10
2022
accepted:
17
04
2023
medline:
30
10
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
ppublish
Résumé
The prevalence of non-alcoholic fatty liver disease (NAFLD) in non-lean patients is significantly increased, and obesity significantly increases the risk of cirrhosis and HCC in NAFLD patients. However, whether there is a difference in clinical manifestations of NAFLD between overweight and obesity remains unclear. The objective of this study was to assess the clinical and histological features of NAFLD among a non-lean population. Current study enrolled consecutive non-lean (body mass index [BMI] >23 kg/m2) patients with NAFLD and available liver biopsy results. Patients were stratified by BMI into two groups for the comparison of their clinical and histological variables, which included the overweight (BMI 23∼<28 kg/m2) and the obese (BMI ≥28 kg/m2). Risk factors for moderate to severe fibrosis (stage >1) were also analyzed through the logistic regression model. Among 184 non-lean patients with metabolic-associated fatty liver disease enrolled, 65 and 119 were overweight and obese, respectively. Patients in the obesity group had a significantly lower level of gamma-glutamyl transpeptidase, higher levels of platelet, glucose, prothrombin time, and more common of moderate to severe inflammatory activity when compared to those in the overweight group. However, a significant low frequency of moderate to severe fibrosis was found in the obesity group versus the overweight group (19.33% vs. 40.00%, p = 0.002). Binary logistics regression analysis of fibrosis found that aspartate transaminase (AST), BMI, alanine transaminase (ALT), and cholesterol (CHOL) were independent predictors for moderate to severe fibrosis in non-lean patients with NAFLD. Compared with the traditional fibrosis-4 (AUC = 0.77) and aminotransferase to platelet ratio index (AUC = 0.79) indexes, the combined index based on AST, BMI, ALT, and CHOL was more accurate in predicting moderate to severe fibrosis in non-lean patients with NAFLD (AUC = 0.87). Clinical and histological features differed between obesity and overweight patients with NAFLD. When compared to the traditional serum markers, the combination index including AST, BMI, ALT, and CHOL provided a better model to predict moderate to severe fibrosis in non-lean patients with NAFLD.
Identifiants
pubmed: 37231905
pii: 000530845
doi: 10.1159/000530845
pmc: PMC10601616
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-434Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Am J Gastroenterol. 2019 Jun;114(6):916-928
pubmed: 31169533
Lab Invest. 2010 Feb;90(2):245-56
pubmed: 19949375
Indian Pediatr. 2017 Oct 15;54(10):825-829
pubmed: 28699612
Platelets. 2010;21(1):29-32
pubmed: 19947902
Zhonghua Gan Zang Bing Za Zhi. 2013 Feb;21(2):116-20
pubmed: 23663883
Intern Med J. 2020 Sep;50(9):1038-1047
pubmed: 31760676
Lab Invest. 2015 Aug;95(8):914-24
pubmed: 26097999
BMC Pediatr. 2021 Mar 12;21(1):122
pubmed: 33711964
Postgrad Med. 2021 Apr;133(3):299-306
pubmed: 32921191
Endocr Pract. 2020 Apr;26(4):444-453
pubmed: 31968197
Diabetes Metab Syndr Obes. 2022 Feb 09;15:383-394
pubmed: 35177915
Liver Int. 2011 Feb;31(2):176-83
pubmed: 21134109
Hepatol Int. 2020 Dec;14(6):889-919
pubmed: 33006093
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Medicine (Baltimore). 2021 Feb 12;100(6):e24743
pubmed: 33578624
Am J Physiol Endocrinol Metab. 2020 Nov 1;319(5):E827-E834
pubmed: 32893671
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Hepatol. 2014 Jul;61(1):98-106
pubmed: 24657401
Hepatology. 2016 Nov;64(5):1774-1784
pubmed: 26934463
J Assoc Physicians India. 2022 Apr;70(4):11-12
pubmed: 35443531
Can J Gastroenterol Hepatol. 2017;2017:6070135
pubmed: 29464178
Liver Int. 2020 Sep;40(9):2082-2089
pubmed: 32478487
Indian J Endocrinol Metab. 2013 Jul;17(4):665-71
pubmed: 23961483
World J Gastroenterol. 2021 Sep 14;27(34):5753-5763
pubmed: 34629799
Expert Rev Gastroenterol Hepatol. 2018 May;12(5):491-502
pubmed: 29609501